Results 241 to 250 of about 251,219 (284)

Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Martina Giacon, Salvatore Terrazzino
wiley   +1 more source

Mortality trends for diabetes mellitus, hypertension and cardiovascular disease among people living with and without HIV in Brazil during the COVID‐19 pandemic, 2020–2022

open access: yesHIV Medicine, EarlyView.
Abstract Introduction People living with HIV (PLWH) face an increasing burden of non‐AIDS‐related chronic conditions. However, how the COVID‐19 pandemic affected chronic disease‐related mortality in this population remains unclear. We assessed changes in mortality among PLWH in Brazil during the COVID‐19 pandemic.
Tatyellen Natasha da Costa Oliveira   +7 more
wiley   +1 more source

Determinants of post-acute COVID-19 syndrome among hospitalized severe COVID-19 patients: A 2-year follow-up study. [PDF]

open access: yesPLoS One
Elias TP   +8 more
europepmc   +1 more source

Efficacy and Safety of Anti‐IL‐4Rα Stapokibart in Elderly Patients With Moderate‐To‐Severe Atopic Dermatitis

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Background Elderly patients with moderate‐to‐severe atopic dermatitis (AD) often exhibit more heterogeneous inflammatory profiles compared with younger adults. To evaluate the efficacy and safety of stapokibart, an anti‐interleukin‐4 receptor α subunit (IL‐4Rα) monoclonal antibody, in different age subgroups.
Yan Zhao   +26 more
wiley   +1 more source

Gut Microbiome Composition and Dynamics in Hospitalized COVID-19 Patients and Patients with Post-Acute COVID-19 Syndrome. [PDF]

open access: yesInt J Mol Sci
Brīvība M   +11 more
europepmc   +1 more source

Common Hematologic Emergencies—Acute Promyelocytic Leukemia and Microangiopathic Hemolytic Anemias—A Pivotal Role of Clinical Laboratory

open access: yesInternational Journal of Laboratory Hematology, EarlyView.
ABSTRACT Hematologic emergencies are urgent health conditions which result in significant mortality and morbidity unless timely therapeutic measures are taken. Therapeutic success depends on their timely and accurate recognition by hematology laboratory services.
Ganna Shestakova   +2 more
wiley   +1 more source

From the ICU Bedside: Applying the Transnational Clinical Academic Doctorate Lens to a Clinically Embedded PhD Journey

open access: yesJournal of Advanced Nursing, EarlyView.
ABSTRACT Aim To critically reflect on a transnational, clinically embedded doctoral journey undertaken during and after the COVID‐19 pandemic, and to draw conceptual and systemic lessons for doctoral education and clinical academic nursing pathways. Background Reflective accounts of doctoral study exist, yet few examine practice‐based PhDs conducted ...
Gideon U. Johnson
wiley   +1 more source

Wearable Electronic Monitoring of Vital Signs in Hospitalised Adults: A Nursing Focused Scoping Review of Clinical, Economic and Implementation Outcomes

open access: yesJournal of Advanced Nursing, EarlyView.
ABSTRACT Aim To synthesise evidence on wearable devices for continuous vital signs monitoring in adult hospital inpatients, focusing on clinical effectiveness, nursing perspectives, workflow impact, patient experience and resource implications. Design Scoping review.
Sian Myfanwy Shaw   +2 more
wiley   +1 more source

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy